CN103948689A - Medicinal composition for treating non-small cell lung cancer and application thereof - Google Patents

Abstract

The invention discloses a pharmaceutical composition for treating non-small cell lung cancer, including targeted drugs, chemotherapy drugs and traditional Chinese medicines, wherein the targeted drugs are selected from bortezomib, imatinib, gefitinib and sunitinib One or more of Nigeria; chemotherapy drugs are selected from one or more of 5-fluorouracil, carboplatin, epirubicin, doxorubicin and fludarabine; Chinese medicine is selected from Danshen, Astragalus, Sappan One or more of Pulsatilla, Pulsatilla and Purslane. The pharmaceutical composition of the present invention has a significant synergistic therapeutic effect when used for the treatment of non-small cell lung cancer, can significantly enhance the tumor suppressing effect, reduce the dosage of drugs, and reduce the toxic and side effects of chemotherapy drugs compared with single drug treatment.

Description

Pharmaceutical composition and application thereof for treating non-small cell lung cancer

technical field

The invention belongs to the technical field of medicines, and in particular relates to a pharmaceutical composition for treating non-small cell lung cancer and its application in treating non-small cell lung cancer.

Background technique

Lung cancer is a disease that results from the uncontrolled growth of cells in the lung tissue. In the past 50 years, the incidence and mortality of lung cancer have increased year by year, and it has developed from a rare disease in the 20th century to the number one cancer killer in the world today. According to statistics, in industrialized countries and many cities in my country, the incidence of lung cancer ranks first among common tumors in men and second in common malignant tumors in women, and it has become the most common cause of death among malignant tumors. It is estimated that by 2025, the number of people dying of lung cancer alone in my country will be close to 1 million each year, becoming the world's largest lung cancer country.

According to the degree of differentiation and morphological characteristics of lung cancer cells, lung cancer is mainly divided into two categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Cell lung cancer accounts for about 85%. Worldwide, NSCLC causes more deaths than prostate, breast, and colon cancer combined. Because NSCLC patients have no obvious features in the early stage, although diagnostic methods and treatment methods have been greatly improved, 70% of NSCLC cancer patients are still at an advanced stage when they are first diagnosed, and about 40% of them lose the opportunity for surgical treatment. Therefore, chemotherapy and targeted therapy are crucial for patients with advanced NSCLC cancer.

However, due to the non-selectivity of chemotherapy, it is difficult to form an effective drug concentration or therapeutic dose in the local tumor. The current chemotherapy method has a certain effect on less than 50% of NSCLC patients, and almost all patients will become drug-resistant during chemotherapy. Lung cancer, leading to failure of treatment. Simply increasing the concentration of chemotherapy drugs is limited by systemic toxicity.

In order to overcome the defects of chemotherapy drugs, people began to develop molecular targeted therapy targeting cell receptors, key genes and regulatory molecules. At present, there are more than ten kinds of molecular targeted drugs used in clinical treatment. For example, imatinib, which targets the Abl kinase that plays an important role in the development of chronic myeloid leukemia, and imatinib and sunitinib, which target the epidermal growth factor receptor-associated tyrosine kinase, and Bortezomib prevents apoptosis-associated protein metabolism by targeting the proteasome. Compared with traditional chemotherapy, targeted drug therapy has the characteristics of strong selectivity and few side effects, and its application in tumor treatment has become more and more extensive. However, the clinical application of targeted drugs also encounters many difficulties. The cost of targeted drugs is very high, and its effectiveness varies greatly depending on individual constitutions, so not everyone can get satisfactory results after spending expensive treatment costs. In addition, drug resistance will inevitably appear during the use of targeted drugs.

Compared with Western medicine treatment, Chinese medicine is also indispensable in cancer treatment. Traditional Chinese medicine can improve the immune function and anti-cancer ability of patients, and help patients survive the recovery period smoothly. However, simple traditional Chinese medicine treatment has disadvantages such as slow effect and inaccurate curative effect, and it is rarely used as the main means of cancer treatment.

Therefore, one of the main goals of the current comprehensive cancer treatment is to find a treatment strategy that can significantly improve the curative effect while effectively reducing the amount of existing drugs and reducing the drug resistance of cancer cells.

Contents of the invention

The invention aims at the deficiencies of the prior art, and provides an anticancer drug composition comprising targeted drugs, chemotherapeutic drugs and traditional Chinese medicines. Specifically, the pharmaceutical composition of the present invention is a mixture of targeted drugs, chemotherapeutic drugs and traditional Chinese medicines in a specific ratio, and the targeted and chemotherapeutic drugs are administered at the same time. Preferably, the targeted drugs, chemotherapeutic drugs Administered with traditional Chinese medicine at the same time.

The drug combination has a specific synergistic therapeutic effect on NSCLC.

In the present invention, "targeted drug" refers to a compound designed for a specific molecular target of a tumor with strong anti-tumor treatment specificity, obvious therapeutic effect, less damage to normal tissue cells, and less adverse reactions. The preferred targeted drug in the present invention is selected from one or more of bortezomib, imatinib, gefitinib and sunitinib. Bortezomib is an apoptosis-inducing proteasome inhibitor that prevents cancer cells from breaking down apoptosis-related proteins. Mainly used in the treatment of multiple myeloma. Imatinib is an Abl-Ber tyrosine kinase inhibitor, mainly used in the treatment of chronic myelogenous leukemia. Gefitinib is an epidermal growth factor receptor inhibitor, mainly used in the treatment of advanced NSCLC. Sunitinib acts on platelet-derived growth factor and vascular endothelial growth factor receptors and is mainly used to treat gastrointestinal stromal tumors and metastatic renal cell carcinoma.

"Chemotherapy drug" refers to a chemical drug that inhibits the growth of cancer cells by blocking cell division. The preferred chemotherapeutic drugs in the present invention are selected from one or more of 5-fluorouracil, fludarabine, carboplatin, doxorubicin and epirubicin. 5-Fluorouracil and fludarabine are antimetabolites. Carboplatin is a DNA cross-linking agent. Doxorubicin and epirubicin belong to the class of topoase inhibitors.

"Chinese medicine" refers to Chinese herbal medicines that can embody the traditional Chinese medicine anti-cancer and anti-cancer principles of strengthening the body, strengthening the body, clearing away heat and detoxification, promoting qi and blood circulation, and softening and resolving hardness. The preferred Chinese medicine in the present invention is selected from one or more of Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Salvia, this product is the dry root and rhizome of Salvia miltiorrhiza Bunge. Excavated in spring and autumn, removed the sediment and dried. Bitter in the mouth, slightly cold; GUIXIN, Liver Channel. It has the functions of dispelling blood stasis and relieving pain, promoting blood circulation and promoting menstrual flow, clearing away heart-fire and relieving restlessness.

Astragalus, this product is the dried root of Astragalus membranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. Excavated in spring and autumn, remove fibrous roots and roots, and dry in the sun. Sweet in taste, warm; returns lung, spleen meridian. It has the functions of invigorating qi and solidifying the exterior, diuresis and detoxification, evacuating pus, suppressing sores and promoting granulation.

Sumac, this product is the dry heartwood of Caesalpinia sappan L., a plant of the genus Fabaceae. More harvested in autumn, remove the white sapwood and dry. Sweet and salty in taste, flat, non-toxic; Guixin, liver, spleen meridian. It has the functions of promoting blood circulation and removing blood stasis, reducing swelling and relieving pain.

Pulsatilla, the dry root of Pulsatilla chinensis (Bge.) Regel, a plant of the Ranunculaceae family. Excavated in spring and autumn, removed the sediment and dried. Bitter in the mouth, cold; Return stomach, large intestine meridian. There is heat-clearing and toxic substances removing, the function of cooling blood and stopping dysentery.

Purslane, this product is Portulaca oleracea L., a plant of the family Portulaca oleracea, which is used as medicine with the whole herb. Sour in taste, cold; enters large intestine, liver, spleen meridian. It has the functions of clearing away heat and promoting dampness, cooling blood and detoxifying.

In the above pharmaceutical composition, preferably, the targeted drug is bortezomib, and the chemotherapeutic drug is 5-fluorouracil.

As a preferred embodiment, the targeted drug in the pharmaceutical composition of the present invention is gefitinib, and the chemotherapy drug is 5-fluorouracil.

Preferably, the targeted drug is bortezomib, and the chemotherapy drug is carboplatin.

Preferably, the targeted drug is imatinib, and the chemotherapy drug is 5-fluorouracil.

Preferably, the targeted drug is sunitinib, and the chemotherapy drug is 5-fluorouracil.

Preferably, the targeted drug is bortezomib, and the chemotherapy drug is epirubicin.

Preferably, the targeted drug is sunitinib, and the chemotherapy drug is doxorubicin.

Preferably, the targeted drug is imatinib, and the chemotherapy drug is doxorubicin.

Preferably, the targeted drug is gefitinib, and the chemotherapy drug is doxorubicin.

Preferably, the targeted drug is sunitinib, and the chemotherapy drug is epirubicin.

Preferably, the targeted drug is bortezomib, and the chemotherapy drug is fludarabine.

Preferably, the targeted drug is bortezomib, the chemotherapeutic drug is 5-fluorouracil, and the traditional Chinese medicine is one or more selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Preferably, the targeted drug is gefitinib, the chemotherapeutic drug is 5-fluorouracil, and the traditional Chinese medicine is one selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Preferably, the targeted drug is bortezomib, the chemotherapeutic drug is carboplatin, and the traditional Chinese medicine is one selected from Danshen, Astragalus, Sumac, Pulsatilla and Purslane.

Preferably, the targeted drug is imatinib, the chemotherapeutic drug is 5-fluorouracil, and the traditional Chinese medicine is one or more selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Preferably, the targeted drug is sunitinib, the chemotherapeutic drug 5-fluorouracil, and the traditional Chinese medicine is one or more selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Preferably, the targeted drug is bortezomib, the chemotherapeutic drug is epirubicin, and the traditional Chinese medicine is one or more selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Preferably, the targeted drug is sunitinib, the chemotherapeutic drug is doxorubicin, and the traditional Chinese medicine is one or more selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Preferably, the targeted drug is imatinib, the chemotherapeutic drug is adriamycin, and the traditional Chinese medicine is one or more selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Preferably, the targeted drug is gefitinib, the chemotherapeutic drug is adriamycin, and the traditional Chinese medicine is one or more selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Preferably, the targeted drug is sunitinib, the chemotherapeutic drug is epirubicin, and the traditional Chinese medicine is one or more selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

Preferably, the targeted drug is bortezomib, the chemotherapeutic drug is fludarabine, and the traditional Chinese medicine is one or more selected from Danshen, Astragalus, Sappan, Pulsatilla and Purslane.

The application of the pharmaceutical composition of the present invention in the preparation of non-small cell lung cancer medicine.

The present invention systematically studies the combined therapeutic effects of different anticancer drug combinations on NSCLC. Specific targeted drugs, chemotherapy drugs and traditional Chinese medicines were found to have different degrees of synergistic effect. Cell experiments prove that the drug combination of the present invention can effectively kill lung cancer cells and inhibit the proliferation of lung cancer cells. The method can effectively reduce drug dosage, reduce drug toxicity, and overcome single drug resistance.

Description of drawings

Figure 1: The growth curve of A549 cells under the single action of different drugs. (A) Growth curve of A549 cells under the action of bortezomib; (B) Growth curve of A549 cells under the action of gefitinib; (C) Growth curve of A549 cells under the action of imatinib; (D) Sunitinib The growth curve of A549 cells under the action of nil; (E) the growth curve of A549 cells under the action of 5-fluorouracil; (F) the growth curve of A549 cells under the action of fludarabine; (G) the growth curve of A549 cells under the action of epirubicin Growth curve; (H) growth curve of A549 cells under the action of doxorubicin; (I) growth curve of A549 cells under the action of carboplatin.

Figure 2: Fa-CI curves of A549 cells under the action of different drug combinations. (A) Fa-CI curve of A549 cells under the combined action of bortezomib and 5-fluorouracil; (B) Fa-CI curve of A549 cells under the combined action of gefitinib and 5-fluorouracil; (C) Bortezole The Fa-CI curve of A549 cells under the combination of rice and carboplatin; (D) the Fa-CI curve of A549 cells under the combination of imatinib and 5-fluorouracil; (E) the combination of sunitinib and 5-fluorouracil The Fa-CI curve of A549 cells under the combined action of ; (F) the Fa-CI curve of A549 cells under the combined action of bortezomib and epirubicin; (G) the combined action of sunitinib and doxorubicin Fa-CI curve of A549 cells; (H) Fa-CI curve of A549 cells under the combined action of imatinib and doxorubicin; (I) Fa-CI curve of A549 cells under the combined action of gefitinib and doxorubicin -CI curve; (J) Fa-CI curve of A549 cells under the combination of sunitinib and epirubicin; (K) Fa-CI curve of A549 cells under the combination of bortezomib and fludarabine ;

Detailed ways

The present invention will be further described below in conjunction with diagram and embodiment.

Example 1: The effects of different combinations of targeted drugs and chemotherapeutic drugs on NSCLC cell lines were evaluated.

Cell Culture: The NSCLC cell line tested in the experiments was A549 cells obtained from ATCC. The cell culture medium used was RPMI medium 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin, and cultured in a _CO2 incubator with a volume fraction of 5% at 37 °C. The cells grew adherently, and the cells in the logarithmic growth phase were used in the experiments.

Screening is done in two parts:

a. In the first set of experiments, the median inhibitory concentration (IC ₅₀ ) value of each drug was determined after 72 hours of exposure to NSCLC cell lines. Specific steps are as follows:

Collect logarithmic phase cells, inoculate in 96-well plate, add 100 μL to each well, adjust the concentration of cell suspension so that each well contains 2000-4000 cells. After 24 hours of culture, the cells were exposed to different concentrations of the drug. The drug concentration was maintained at 7-8 concentration gradients, and a blank group and a positive control group were set up, and 5 replicate wells were set for each concentration. After culturing for 72 hours, add 20 μL of MTT solution (5 mg/ml, ie 0.5% MTT) to each well, continue culturing for 4 hours, centrifuge the 96-well plate at 2000 rpm, and discard the culture solution using the siphon principle. Add 150 μL dimethyl sulfoxide to each well and shake on a shaker for 10 min. The absorbance value (OD value) of each well was measured at a wavelength of 490 nm on a microplate reader. The cell growth inhibition rate was calculated according to the following formula: growth inhibition rate=(1-absorbance value of the experimental group/absorbance value of the control group)×100%. Experiments were repeated three times. Draw the dose-effect curve (Fig. 1) and calculate the _IC50 value of each drug as shown in Table 1.

Table 1: IC ₅₀ values of single drugs in NSCLC cell lines

b. In the second set of experiments, the inhibitory effects of various anticancer drug combinations mentioned above on NSCLC cell lines were determined. Drugs are combined in experiments at fixed dose ratios that correspond to a single IC50 value for each drug alone. The drug concentration was maintained in 78 concentration gradients. Finally, the combination index (CI) was calculated by the Chou-Talalay equation to evaluate the synergistic effect of the drug combination:

$\mathrm{<span\; class="notranslate">\; CI</span>}<span\; class="notranslate">\; =</span>\frac{{<span\; class="notranslate">\; (</span>\mathrm{<span\; class="notranslate">\; D.</span>}<span\; class="notranslate">\; )</span>}_{\mathrm{<span\; class="notranslate">\; 1</span>}}}{{<span\; class="notranslate">\; (</span>{\mathrm{<span\; class="notranslate">\; D.</span>}}_{\mathrm{<span\; class="notranslate">\; x</span>}}<span\; class="notranslate">\; )</span>}_{\mathrm{<span\; class="notranslate">\; 1</span>}}}<span\; class="notranslate">\; +</span>\frac{{<span\; class="notranslate">\; (</span>\mathrm{<span\; class="notranslate">\; D.</span>}<span\; class="notranslate">\; )</span>}_{\mathrm{<span\; class="notranslate">\; 2</span>}}}{{<span\; class="notranslate">\; (</span>{\mathrm{<span\; class="notranslate">\; D.</span>}}_{\mathrm{<span\; class="notranslate">\; x</span>}}<span\; class="notranslate">\; )</span>}_{\mathrm{<span\; class="notranslate">\; 2</span>}}}$

In the formula, (D _x ) ₁ and (D _x ) ₂ represent the concentration at which the inhibition rate of the two drugs is x% when the two drugs exist alone. (D) ₁ and (D) ₂ indicate the concentration at which the inhibition rate reaches x% when the two drugs are present at the same time. CI<1, =1, and >1 indicate synergistic, additive, and antagonistic effects, respectively (Chou TC and Talalay P. Adv. EnzymeRegul. 1984, 22, 27-55). CompuSyn software (ComboSyn, Inc, Paramus, NJ) was used for CI Combination Index analysis (Figure 2). Since the combined effect at high inhibition rate is more important than at low inhibition rate in cytotoxicity experiments, we defined a weighted CI to quantify the combined effect: CI _wt = [CI ₅₀ + 2CI ₇₅ + 3CI ₉₀ + 4CI ₉₅ ]/10, the subscripts represent different inhibition rates. Table 2 provides the Combination Index (CI) obtained when different dose combinations were applied to the A549 cell line.

Table 2: CI values obtained when the drug combination was applied to the A549 cell line

experiment result shows:

The combination of bortezomib and 5-fluorouracil has a strong synergistic effect (CI<0.1).

Gefitinib and 5-fluorouracil, bortezomib and carboplatin, and imatinib and 5-fluorouracil had strong synergistic effects (0.1<CI<0.3).

sunitinib and 5-fluorouracil, bortezomib and epirubicin, sunitinib and doxorubicin, imatinib and doxorubicin, gefitinib and doxorubicin, sunitinib and Six combinations of epirubicin had synergistic effect (0.3<CI<0.7).

The combination of bortezomib and fludarabine was weakly synergistic (0.85<CI<0.9).

Example 2: The influence of Salvia miltiorrhiza on the anti-cancer effect of targeted drug and chemotherapeutic drug combination was evaluated.

Preparation of Salvia miltiorrhiza water extract: 80g of Salvia miltiorrhiza was decocted for 3 times, filtered through a vacuum filter, concentrated into about 40ml of medicinal solution, put into a vacuum drying oven to dry, and the yield was calculated as 100% concentration. Take 1g of the water extract, add 10ml of ultrapure water, dissolve, centrifuge, take the supernatant, and then sterilize it through a 0.22μm microporous membrane to make a mother liquor with a concentration of 100mg/ml, and store it in a -20°C refrigerator for later use.

The steps and methods of the cell experiment were the same as those in Example 1, except that a drug-dosing group was added, in which the combined amount of targeting and chemotherapy drugs remained unchanged, but 10 mg/ml of Danshen water extract was added. The results are shown in Table 3. After adding Danshen water extract, the IC ₅₀ values of targeting and chemotherapeutic drug combinations on A549 cells all decreased to a certain extent, indicating that Danshen water extract can enhance the combination of targeting and chemotherapeutic drugs. Anticancer effect.

Example 3: The effect of Astragalus membranaceus on the anti-cancer effect of targeted drug and chemotherapeutic drug combination was evaluated.

Preparation of astragalus water extract: 80g of astragalus was decocted for 3 times and the medicinal liquid was filtered through a vacuum filter, concentrated into about 40ml of medicinal liquid, put into a vacuum drying oven for drying, and the yield was calculated as 100% concentration. Take 1g of the water extract, add 10ml of ultrapure water, dissolve, centrifuge, take the supernatant, and then sterilize it through a 0.22μm microporous membrane to make a mother liquor with a concentration of 100mg/ml, and store it in a -20°C refrigerator for later use.

The steps and methods of the cell experiment were the same as those in Example 1, except that a drug-dosing group was added, in which the combined amount of targeting and chemotherapy drugs remained the same, but 10 mg/ml of astragalus water extract was added. The results are shown in Table 3. After adding the water extract of Astragalus membranaceus, the IC ₅₀ values of the combination of targeting and chemotherapy drugs on A549 cells decreased to a certain extent, indicating that the water extract of Astragalus membranaceus can enhance the combination of targeting and chemotherapy drugs. Anticancer effect.

Example 4: The influence of sumac on the anti-cancer effect of targeted drug and chemotherapeutic drug combination was evaluated.

Preparation of Sappan water extract: 80g Sappan decocted for 3 times, filtered through a vacuum filter, concentrated into about 40ml of liquid, put into a vacuum oven for drying, and calculate the yield as 100% concentration. Take 1g of the water extract, add 10ml of ultrapure water, dissolve, centrifuge, take the supernatant, and then sterilize it through a 0.22μm microporous membrane to make a mother liquor with a concentration of 100mg/ml, and store it in a -20°C refrigerator for later use.

The steps and methods of the cell experiment were the same as those in Example 1, except that a drug-dosing group was added, in which the combination of targeting and chemotherapeutic drugs remained unchanged, but 10 mg/ml hematoxylin water extract was added. The results are shown in Table 3. After adding hematoxylin water extract, the _IC50 values of targeting and chemotherapeutic drug combination on A549 cells all decreased to a certain extent, indicating that sumac water extract can enhance the anticancer effect of targeting and chemotherapeutic drug combination. effect.

Example 5: The effect of Pulsatilla pulsatillae on the anticancer effect of the combination of targeted drugs and chemotherapeutic drugs was evaluated.

Preparation of water extract of Pulsatilla pulsatillae: 80g of Pulsatilla pulsatillae was decocted for 3 times, filtered through a vacuum filter, concentrated into about 40ml of liquid medicine, dried in a vacuum drying oven, and the yield was calculated as 100% concentration. Take 1g of the water extract, add 10ml of ultrapure water, dissolve, centrifuge, take the supernatant, and then sterilize it through a 0.22μm microporous membrane to make a mother liquor with a concentration of 100mg/ml, and store it in a -20°C refrigerator for later use.

The steps and methods of the cell experiment were the same as those in Example 1, except that a drug-dosing group was added, in which the amount of the combination of targeting and chemotherapy drugs remained unchanged, but 10 mg/ml of Pulsatillae water extract was added. The results are shown in Table 3. After the water extract of Pulsatillae was added, the _IC50 values of the combination of targeting and chemotherapy drugs on A549 cells decreased to a certain extent, indicating that the water extract of Pulsatillae can enhance the combination of targeting and chemotherapy drugs. Anticancer effect.

Example 6: The effect of purslane on the anticancer effect of targeted drug and chemotherapeutic drug combination was evaluated.

Preparation of Purslane water extract: 80g Purslane decocted for 3 times, filtered through a vacuum filter, concentrated into about 40ml medicinal liquid, put into a vacuum oven for drying, and calculate the yield by 100% concentration. Take 1g of the water extract, add 10ml of ultrapure water, dissolve, centrifuge, take the supernatant, and then sterilize it through a 0.22μm microporous membrane to make a mother liquor with a concentration of 100mg/ml, and store it in a -20°C refrigerator for later use.

The steps and methods of the cell experiment were the same as those in Example 1, except that a group of drug administration groups was added, in which the combination of targeting and chemotherapy drugs remained unchanged, but 10 mg/ml of purslane water extract was added. The results are shown in Table 3. After the water extract of purslane was added, the _IC50 values of the combination of targeting and chemotherapeutic drugs for A549 cells all decreased to a certain extent, indicating that the water extract of purslane can enhance the targeting and chemotherapeutic effects. Anticancer effects of chemotherapeutic drug combinations.

Table 3: Effects of different traditional Chinese medicines on the combination of targeted and chemotherapeutic drugs on NSCLC cell lines

The specific embodiments of the present invention have been described in detail above, but they are only examples, and the present invention is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modifications and substitutions to the present invention are also within the scope of the present invention. Therefore, equivalent changes and modifications made without departing from the spirit and scope of the present invention shall fall within the scope of the present invention.

Claims (5)

1. The pharmaceutical composition for the treatment of non-small cell lung cancer, characterized in that, the pharmaceutical composition includes targeted drugs, chemotherapeutics and traditional Chinese medicine; wherein, the targeted and chemotherapeutic drugs are administered simultaneously, the Targeted drugs, chemotherapeutic drugs and traditional Chinese medicines are administered at the same time. 2. The pharmaceutical composition for the treatment of non-small cell lung cancer according to claim 1, wherein the targeted drug is selected from one of bortezomib, imatinib, gefitinib and sunitinib one or more species. 3. The pharmaceutical composition for the treatment of non-small cell lung cancer according to claim 1, wherein the chemotherapeutic drug is selected from the group consisting of 5-fluorouracil, carboplatin, epirubicin, doxorubicin and fludarabine one or more. 4. The pharmaceutical composition for treating non-small cell lung cancer according to claim 1, wherein the traditional Chinese medicine is selected from one or more of Danshen, Astragalus, Sappan, Pulsatilla and Purslane. 5. The use of the pharmaceutical composition according to any one of claims 1-4 in the preparation of non-small cell lung cancer medicine.